{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:48:59Z","timestamp":1794948539275,"version":"4.9.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00520-023-07987-x","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T04:01:26Z","timestamp":1691812886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series"],"prefix":"10.1007","volume":"31","author":[{"given":"Jamie MJ","family":"Weaver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehek","family":"Chaudhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Lilleker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"7987_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunotherapy Cancer 7:134","journal-title":"J Immunotherapy Cancer"},{"key":"7987_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","volume":"130","author":"T Cooksley","year":"2020","unstructured":"Cooksley T, Gupta A, Al-Sayed T, Lorigan P (2020) Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer 130:193\u2013197","journal-title":"Eur J Cancer"},{"issue":"1","key":"7987_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","volume":"152","author":"T Mikami","year":"2021","unstructured":"Mikami T, Liaw B, Asada M et al (2021) Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neuro-Oncol 152(1):135\u2013144","journal-title":"J Neuro-Oncol"},{"issue":"12","key":"7987_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E et al (2021) Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052\u20131061","journal-title":"Oncologist"},{"issue":"1","key":"7987_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319","journal-title":"J Immunother Cancer"},{"issue":"11","key":"7987_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134","journal-title":"Neurology"},{"issue":"12","key":"7987_CR7","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1007\/s00520-020-05710-8","volume":"28","author":"ME Suarez-Almazor","year":"2020","unstructured":"Suarez-Almazor ME, Pundole X et al (2020) Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care Cancer 28(12):6159\u20136173","journal-title":"Support Care Cancer"},{"issue":"3","key":"7987_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"key":"7987_CR9","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for Immunotherapy of Cancer (SITC) Clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435","journal-title":"J Immunother Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07987-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07987-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07987-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:10:00Z","timestamp":1694754600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07987-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["7987"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07987-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"22 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study with no ethical approval required. Local institutional board number: 3180.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"518"}}